The insight-to-action era in hereditary cancer risk
Roughly 1 in 20 individuals carry a genetic mutation that increases their risk for cancer, yet most remain unaware. As precision medicine advances and access to genetic testing expands, the ability to identify at-risk patients has never been more attainable.
The harder problem is what happens next. Health system leaders describe a system where high-risk patients are flagged but then drift — between a positive screen and a genetic counselor, between a test result and ongoing imaging, between a recommendation and a coordinated care plan. As patient volumes grow, those gaps grow with them. And a national shortage of genetic counselors means scaling through hiring alone isn't realistic.
Becker's Healthcare convened health system leaders for a candid advisory call on how organizations are closing this gap.
Inside the report:
The harder problem is what happens next. Health system leaders describe a system where high-risk patients are flagged but then drift — between a positive screen and a genetic counselor, between a test result and ongoing imaging, between a recommendation and a coordinated care plan. As patient volumes grow, those gaps grow with them. And a national shortage of genetic counselors means scaling through hiring alone isn't realistic.
Becker's Healthcare convened health system leaders for a candid advisory call on how organizations are closing this gap.
Inside the report:
- The multi-pronged approaches leaders are using to identify high-risk patients at scale
- How systems are reserving genetic counselor time for nuanced post-test counseling
- The trade-offs between centralized high-risk clinics and primary-care-coordinated follow-up
- How leaders are measuring downstream revenue to justify program investment
Please fill out the form to download the whitepaper.